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'rh¢ 126-residue proi¢ina~= (PR) of bovine leukemia virus (BLV} was synthesized by ~olid-ph~,~ p~ptid¢ s~th~is and its activity was shown usin$ 
various oliltol:~ptld¢ substrat©s reprcr=:ntinll c =tvalla rdt~ in BLV, human T-call leukemia virus tyl~ I (HTLV- 1), murinc leukemia virus (MuLV) 
and human immunod¢fieieney virus type 1 (H IV-I}. The specificity of the BLV PR was also temporal to that of chemically synthesized human 
immunodefieienc3, virus tylX 2 (HIV.2) Pg, Many of the l~ptides were cleaved at the exp¢=ted site. however, 6 out of IS were hydroly'z~d only 
by one of the Pgs, Furthermore. one BLV peptide was proc¢:ss~d iffer=ally by the two cnaym~, Them results, tOll=that with the relative activiti~ 
and the lack of inhibition of BLV PR by two HIV.I PR inhibitor~, sUlll~t that the flLY PR specificity is substantially different from that of HIV 
PRs. 
Solid phar~ pcptidc synthe=ig BLV proteinas¢: Substratc specificity 
I. INTRODUCTION 
Human {mmunodeficicncy viruses (HIV) and human 
T.cell leukemia viruses (HTLV) arc intcnsivcb, studied, 
since they are the causative agents of a~uir©d immu. 
nodeficiency syndrome (AIDS) and adult T-~II leuke- 
mia (ATL). resp~tively [1]. The retroviral proteinas¢ 
(PR), especially that of HIV has also received a great 
deal of  attention as a potential target for chemotherapy 
[2], since the PR activity is r~uired for the maturation 
and infectivity of the viruses [3-5]. The lentiviral Pg is 
also suggested to be involved in the early phase of viral 
life-cycle [6--8], However. far less is known about the 
HTLV Pg,  the proteolytic enzyme of th= first bona fide 
human retrovirus, which has oniy b~n recently cloned 
[9]. 
Bovine leukemia virus (BLV) is the etiologic agent for 
enzootic bovine leukosis [10], which is an economically 
important disease of cattle. BLV shows the closest rela- 
tionship to HTLV [I I-I 3]. therefore, as the virus itself, 
BLV  Pg  can also be considered as a model of HTLV- I  
PR. 
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We have used solid phase peptide synth~is to pro- 
duce the prot¢olytic enzyme of BLV. Previously, BLV 
PR has b~n obtained from purified virus, and partially 
characterized [14]. It is ¢ompo ',~xl of 126 residue, and 
it is the larger known retroviral proteinase. In this 
study the substrate specificity of the BLV PR was com- 
pared to that of  also chemically synth~ized HIV-2 pro- 
teinas¢. 
2, MATERIALS AND METHODS 
2, I. S)'.thezis of pcptid)'l.rexin, h,)'deogen fluoPide /eat,age and refoldo 
tnfl 
Solid phar,¢ pcptid¢ syathclis was performed usinll a Vega Coupler 
250C peptide synthesizer (DuPont Co.), ztartinli with 330 roll (0,25 
stool) Boc.Gly.phenylac~tamidommhyl re.in (Appli~ niosyztems, 
lno,), with a prolPam which has be~n dc~ribcd curlier [15], Eight 
equivalents of protected amino acids (Baehcm, Inc.) were used in each 
cycle, The side chain-protecting Ilroups were I~nzyl 5~r Asp, Glu. ,~r. 
Thr; 2.chloro~ru~loxycar~nyl for Lys; 2-bromo-~azyloxycarbonyl 
for Tyr; formyl for Trp and tosyl for Arll, At the end of the 12S-cycle 
synthesis, the pcptidyl-resin weighed 2,06 II. The peptide was cleaved 
from the r~in by the following different ways (using 270--270 m S 
aliquots): 6) stirring for 1 h at 0'C in the mixture of liquid HF (8 ml) 
and p.cresolc (0,3 rnl); (iS) stirrinlt for I h at 0*C in the mixture of liquid 
HF (12 ml), anisol¢ (1 ml). and ethanedithiole (l ml); (lid by low-hillh 
cleave@ ac¢ordinll toTam et al. [16], The crude peptides (25-25 mid 
were dizmlw.d in 2 ml 8 M 8uanidinc-HCl, purified by RP.HPLC, and 
refoldcd with 20 mM PIPF...S.HCI, pH 7.0, containing I mM EDTA, 
100 mM NaCI. 10% ll;lyc=rol, 5% ethyl=he ~lycol and 0.5% Nonidet 
P-40, a,~ dczcrib~ for H1V-2 PR [I 7], Amino acid composition of the 
obtained protein was determined after hydrolysis in 6 M HCi (110°C. 
20 h)on a D urrum D.500 anallfz~r. Peptide obtained with HF ¢leava• 
protocol (it) was further purified by ~i n-qtration  a Superdex G.?5 
HR-IU60 column (Pharmacia LKB Biot¢chnology) and purified 
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again on RP-HPLC at described for HIV.2 PR [l'/I, The rcfoldcd 
protcinas¢ ~tution was concentrated using Amicon-3 concentrator, 
SDS-PAGE of the purified FR was performed according to Laemmli 
[~al, 
..2.2, Oligopeplides 
Olijol~=ptides were synthesb'xd by solid.pha~ peptidc synthesis on 
a Model 430A aatomated p~ptidc syathasizer (Applied Biosystems. 
Inc,) or on the Vei|a Coupler 2S0C using Boc chemistry, and ~=rc 
purifi¢d by RP.HPLC. Stock solutions and dilutions were made in 
distilled water (or in ~ mM dithiothr¢itol for the Cys.contalninl pep 
tide), and the prefer peptid¢ concenmLtion was determined by amino 
acid analysis on either a Dun'urn D-$O~ or a Waters Pieo-Tall arm. 
ly'aer. 
2.3. Prulei.as¢ ass.y 
Prot¢inas¢ asmys ~¢rc pwformed at 3"PC usinit chemically synthe. 
sized BLV and HIV-2 PRs [17.19-21| in 0,2S M potassium phosphate 
buffer, pH 5.6. containing 7.$% ~lycerol. S mM dithiothreitol. I mM 
EDTA, 0.2~ Nonidet P.40 a=~ 2 M NaCI, followed by the separation 
of the substrates and cleavage pr~lucts by RP-HPLC as it was d¢. 
~r i~d [ I 5,17,20,21 ], Amino acid anal>sis of the colh'¢ted i~aks was 
u~d to confirm the eleavaile site in the sul~trates. 
3, RESULTS AND DISCUSSION 
3. I. Chemical s)'nthesis of the BL V protehuts¢ 
While earlier techniques limited chemical peptidc syn, 
thesis to produce only relatively small biologically ac- 
tive oligopcptides and enzymes like ribonucleases 
[22.23]. tee, cat developments and automatization f the 
solid-phase peptide syathesi~ have made it possible to 
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FiB. I. Rev=rsc, d.phas~ HPLC purification of chemically synth~tzed 
[tLV prozeinas=. The polypeptide was cleaved from the resin by HF 
in the prcrcnce of anisol¢ and ethanedithiole, purified by reversed, 
phas¢ HPLC, then purified by 8¢1 filtration in 6 M Guanidine.HCl. 
100 mM Tris-HCl, The peak fraction of the ~=l filtration was a¢idifi=d 
to pH 2 by the addition of TFA and applied to a/~llondapak Cil¢ 
column (19 x 150 ram), The proteinase was elated with an acetonitril= 
gradient into water in the presence of 0,05% TFA, Fraction= wer= 
collected manually, lyophilized and rcfolded as described Insc.ction 2. 
Activity was measured urine the oligopeptide KTKVL.VVQPK (rep- 
re~nting tlm CgJNC cleavage slt~ in HT-L;V-I}. insert shows th= 
purity of the peak fraction (fractina 5) of RF-HPLC on SDS.poly- 
aerylamid= gel, The protein was stained with Coomassic brillant blue 
R-2~0. 
produce larger biologically active polypeptid¢ mole- 
cules [24-26], including the 9g-residue HIVol and HIV- 
2 PRs [19,27.28]. However, the routine synthesis of 
large peptides (over 50 residues) has not yet been com- 
pletely resolved. Although BLV PR has already been 
expressed in a bacterial expression vector [29], chemical 
synthesis may have some advantall~: it is less labouri- 
ous, taster, and contamination/degradation by cellular 
proteinas¢~ is not a concern. 
Using the solid phase peptide synthesis, w= were able 
to prepare the BLV PR, a 126 residue polypeptid¢, so 
far the largest proteinase which has been chemically 
synthesized, Peptidu obtained with any of the HF 
cleavage method showed a=tivity after refoldinB, how- 
ever, the peptide subjected to HF cleavage protocol (iS) 
had the highest specific activity (data not shown). The 
amino acid composition of the peptide obtained with 
cleavage method (iS) and RP-HPLC purification was 
determined tobe as follows (the number= inparentheses 
represent the expected values): A,~x 9,63 (10): Thr 5.08 
(5): Set 7.39 (9); (}Ix 10.60 (11); Pro 13.88 (14); Gly 9.61 
(9): Ala 8.96 (9): Val 10.85 (11); Met 2.01 C2); I1¢ 7.36 
(8); Lea 16.91 (17): Tyr 3.11 43); Phe 2.41 (2)i Lys 3.74 
(3); Arg 8.45 (9): Trp was not determined. N terminal 
sequence analysis performed up to 22 rcnidues with a 
model 470A gas-phase .sequencer (Applied Biosystcm=, 
Inc.) ~ve the proper sequence. The pcptid¢ was further 
purified by gel filtration and RP, HPLC. The last purifi- 
cation step is shown in Fig. 1. The peak fraction of the 
HPLC separation was active after refolding and it was 
found to be homogenous using SDS-PAGE (Fig. I) 
having the expected molecular weight (15 kDa). The 
active fraction elated on the RP-HPLC at 50% aeetoni- 
trile which is in good agreement tothat found with the 
viral enzyme (52-55%) [30]. This preparation was able 
to cleave p=ptides in a time-dependent manner. The 
cleavage of the peptid¢ KTKVL*VVQPK tbllowcd the 
Micha=lis-Menten ki etics with an apparent K,. of 0.05 
mM and apparent K,~, of 0.4 nmol.s'Umg "~(using 1 h 
incubation time). 
3.2. Sg¢cificity uf BL V grot¢inas¢, comparison to that of 
chemically syadaeM:ed HfV-2 prateinase 
Oligopeptides representing determined cleavage siren 
in the polyproteins of BLVo HTLV, I, MuLV and HIV, 
1 were investigated assabstraten of BLV PR. To corn. 
par= the substrate specificity of BLV PR with HIV-2 
PR, the peptidcs were also investigated assubstrates of 
chemically synthesized HIV-2 PR. 
Oligopeptides representing known Gag and Gag-Pro 
cleavage sites in BLV were all hydrolyzed by the BLV 
PR (Table I). Similar results w~¢ found with BLV PR 
expressed inE. call [29], This suggests, that the ratterS. 
ral PR may be able to process the respective polypro- 
teins, as it was suggested for HIV-I and HIV-2 PR, 
using the same approach [20,31]. However, one BLV 
cleavage site peptide (peptide 2) was not hydrolyzed by 
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Table l 
Comparison of the tub~trate Ipccificity o£ ehomimlly ~,nthe~ized BLV and HIV-2 pro~in~,~ 
S~p~mbcr 1992 
Peptid~ Repre~nted Relative aciivit,,P 
¢le~va~ site 
BLV PR HIV-2 PR 
1. PPA[L®PliSE BLV MAJCA ~' 1.00 1.00 
2. KQPAILeVHTPG BLV CMNC 0.~0 not hydrolyzt, d' 
3. ELECL, LSIPL BLV TFli~R 0.32 0, I P 
4. PP~VG.VLDAP BLV PR/p3 0.20 0.23 
$. APQVL*PVMHP HTLV.I MA/CA 1.2 1.5 
6. KTKVLeVVQPK HTLV-i CMNC i.9 3. ! 
?. DPASIL.PVIP HTLV-I TF/PR 0.~2 not hydrolyt.~d ~ 
8. RSSLYoPALTP' MuLV MAJpi2 0.02 12,4 
9. TSQAFoPLRAG' MuLV pl 2,'CA 0.21 11.~ 
10. MSKLLoATV'VS' MuLV CMNC 0.07 not hydroiyr, ed' 
I h POTSLL~TLDDQ' MuLV NCJPR 0.14 not hydrolized ~ 
12. VSQNY,,PWQ H|V.I MAJCA not hydrolyzed' 28.8 
13. KARVL~AEAMS HiV.I CA/X 0,1~ 0,1 
14. TATIM,MQ~GN HIV.I YdNC 0.16 26.9 
15. VSFNF, PQITL H IV.i TF/PR not h~rol :~d'  0.25 
"ActivitLes were m~sured at 0.2 mM substrate concentration, and m relative activity wu exp _r~___~'~_ the ~tivity on a l~v~n pgptid~ divided by 
the aedvi[y obtained for each enwrne with p~otide I. 
~' MA, matrix protein; CA, cap~id protein; X, peptide between MA and CA in HiV-I Oql; NC, nuclcocap~id prolein; TF, tran,~fr.~n¢ protein; Pit,, 
retrovirai prot¢iner¢ (rctrovinsl protein nomenclature from Lets rt el, [37]). CleavaBe sites am indicated by ¢sterJsks, and Liken from [9.36]. 
' Hot hydrolx'~d -ring 24 h incubation. 
'~ Thi~ pcptid¢ was hydroiyaed by the HiV.2 PR at the -Cys*L.~u. bond, in~tead of the -Lcu*Lcu. bond found by the BLV PR, 
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PR [12,|4]; HTLV-I PR [9]; HIV.2 PR [19]. Compnrison is based on multiple alignment [3S]. Tho,ae amino aci~ which are prcdiccd to b¢ in':olvcd 
in the enzyme.s,bstrate interaction,, (S,,.S/region) ba~.d on the strucLure~ of HIV.I PR.inhibiter ¢omplc~ [39-4l] end moi~ular mnd~iin~ of 
HIV.PR ',ub~trat¢ and inhibiter interactions [17,42] are boxed. 
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the HIV-2 PR. while another one (peptid¢ 3) was hydro- 
lyzed differently, at the .Cys*I.¢u- bond instead of the 
.l.¢u*lJu- bond. 
The BLV PR was also able to hydrolyzc the HTLV-I 
cleavage site peptides at the expected site (Table l). In 
fact. the highest relative activity was obtained with the 
oligopeptide representing the CA/NC cleavage ~ite in 
HTLV-I (peptide 6), which was also sufficiently hydro- 
lyzed by the HIV-2 Pg, 
Since it has been noted earlier, that the HTLV/BLV 
cleavage site.s are homologous to the MuLV cleavage 
sites [32], w= also inv==tisated the cleavage of oligopep- 
tides representing four MuLV Gag and Gag-Pol cleav- 
age sites. In accordance with the cleavage site homol- 
o&% these peptides were also hydroly'zed by the BLV Pg 
at the expected site (Table I). Although two of the pep- 
tides representing MuLV cleavage sites were also sub- 
strates for HIV-2 PR, two of them were hydrolyzed only 
by the BLV PR. 
Two peptides of HIV-I cleavage site sequen~s were 
not hydrolyzable by the BLV PR. while one of them 
(peptide 12) was the most efficient substrate of HIV-2 
Pg from the ~lected peptides, These results suggest, 
that the HIV proteinase has a substrate specificity dis- 
tinct from that of the BLV (and possibly the HTLV) PR. 
3.3, Lack of inhibttion of tile BLV PR b), inhibitors of 
HIV proteinaz'e= 
Two specific inhibitor= of HIV prot¢inases, SP-346 
[33] and a phosphinicomethyl isoster¢ (Compound 3 
[34]) were assayed as inhibitors of BLV Pg. None of 
these inhibitors were able to inhibit the BLV PR up to 
the highest concentration assayed (40,/zM and I/tM, 
r~pectively), while both were able to inhibit completely 
HIV-2 PR under identical conditions (ICso values were 
8/~M and 0.02/JM, respectively). This result further 
emphasizes the differen~s between the HIV and BLV 
proteinases. The lack of inhibition with SP-346 is not 
surprising, since it is a pipecolic acid contaitfing analog 
of SP-2l I, an HIV Pg substrat¢ (peptid¢ 12 in Table I). 
which is not hydrolyzed by the BLV PR, This peptide 
contains atypical Class I cleavage site of the immunode- 
ficiency viruses having Asn at P=, aromatic amino acid 
at Pt and Pro at P{ position [35]. Since another peptide 
representing Class 1 cleavage site was also not hydro- 
lyzed by BLV PR (peptide 15), the typical Class 1 cleav- 
age sites of HIV are not efficient substrates of BLV PR. 
In this regard, it is important to point out, that -Tyr/ 
Phe*Pro- cleavage site does not occur in BLV and 
HTLV Gag polyproteins [36], 
Although the HIV-2 PR substantially differs in size 
and amino acid composition from BLV and HTLV-I 
PRs, many of th= amino acids expected to be involved 
in enzyme-substrate interaction are conserved (Fig. 2). 
However, certain amino acid changes at the crucial 
parts of the substrate binding pocket like the change of 
Ile s° to Ala at the tip of the flap or the change ofThP °. 
ProS'-lle '~ as part of the S,-S,' binding pockets may be 
r~ponsible for the substantial ditTcren¢¢s in Sl~Cificity 
of the HIV and BLV proteinases. 
HIV proteinases are. potential targets for chemother. 
spy [2]. By analog, it ma~. b~ possible to treat ATL and 
enzootic bovine leukosis by administration f inhibitors 
of HTLV and BLV PRs. However, our initial r~ults 
indicate, that the BLV Pg (and po~ibly the HTLV PR) 
has a substantially different substrate specificity from 
that of HIV Pgs, as also sugg~ted by others [29]. 
Therefore it is likely, that inhibitors designed against the 
HIV Pgs will not be suitable in therapy of" enzootic 
bovine leukosis and ATL, 
The pretense of HTLV-1 has r~.=ntly been expressed 
in E. coil [9]. The availability of both BLV and HTLV-I 
PRs will allow comparative studies of their substrate 
specificity, 
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